KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBITDA Margin (2016 - 2026)

Pacific Biosciences Of California has reported EBITDA Margin over the past 16 years, most recently at 90.33% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 9349.0% year-over-year to 90.33%; the TTM value through Dec 2025 reached 341.45%, down 14040.0%, while the annual FY2025 figure was 341.45%, 14040.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 90.33% at Pacific Biosciences Of California, up from 98.47% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 3.16% in Q4 2024 and troughed at 1146.92% in Q1 2025.
  • A 5-year average of 238.29% and a median of 195.57% in 2021 define the central range for EBITDA Margin.
  • On a YoY basis, EBITDA Margin climbed as much as 37614bps in 2025 and fell as far as -94413bps in 2025.
  • Year by year, EBITDA Margin stood at 195.57% in 2021, then tumbled by -55bps to 303.03% in 2022, then surged by 55bps to 137.02% in 2023, then soared by 102bps to 3.16% in 2024, then tumbled by -2957bps to 90.33% in 2025.
  • Business Quant data shows EBITDA Margin for PACB at 90.33% in Q4 2025, 98.47% in Q3 2025, and 105.73% in Q2 2025.